Renal cell carcinoma · line 1 · Lenvatinib + pembrolizumab (RCC, 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-LENV-PEMBRO-RCC |
| ID | IND-RCC-METASTATIC-1L-LENV-PEMBRO |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-03 | pending_clinical_signoff |
| Diseases | DIS-RCC |
| Sources | SRC-CLEAR-MOTZER-2021 SRC-ESMO-RCC-2024 SRC-NCCN-KIDNEY-2025 |
Notes
Highest response rate and PFS of 1L ccRCC options. Reserve for fit, hypertension- manageable patients where response magnitude matters most. Active BP management is essential from day 1. Lenvatinib dose reductions (20→14→10→8 mg) are very common (69%) and do not appear to compromise efficacy.
Used By
Algorithms
ALGO-RCC-METASTATIC-1L- ALGO-RCC-METASTATIC-1L